“There has been increasing interest in developing factor XIa inhibitors to prevent harmful thrombosis, while preserving normal clotting processes to minimise bleeding. We conducted the LIBREXIA ACS trial to assess the efficacy and safety of the selective factor XIa inhibitor, milvexian, after ACS when added to standard antiplatelet therapy.”
Dr. Philippe Gabriel Steg ↗